Percheron Therapeutics Limited (PER.XA)
Cboe AU · AUD
A$0.0035 (+0.00%) as of
Key statistics
- 52-week range
- 0.0020 – 0.0100
- Beta
- 1.12
- Revenue (TTM)
- 843.6k
- Profit margin
- 0.00%
- Volume
- 200.00k
About Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.